Compare SURG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | LTRN |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 49.9M |
| IPO Year | N/A | 2020 |
| Metric | SURG | LTRN |
|---|---|---|
| Price | $1.62 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 109.5K | 73.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,372,555.00 | N/A |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $122.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $2.55 |
| 52 Week High | $3.47 | $6.12 |
| Indicator | SURG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 38.84 |
| Support Level | $1.40 | $3.72 |
| Resistance Level | $1.90 | $3.98 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 34.98 | 9.51 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.